


Company Registration No. 04216368 (England and Wales)

PCT Shareholders Limited
(formerly Pro-Cure Therapeutics Limited)

Unaudited Abbreviated Accounts
For The Year Ended 30 April 2013

MONDAY



A2ZGZ2SB

A06

13/01/2014

#132

COMPANIES HOUSE

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)
CONTENTS

	Page
Abbreviated balance sheet	1 – 2
Notes to the abbreviated accounts	3 – 5

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)

**ABBREVIATED BALANCE SHEET
AS AT 30 APRIL 2013**

	Notes	£	2013 £	£	2012 £
Fixed assets					
Tangible assets	2		-		35,283
Current assets					
Debtors	3	27,749		76,311	
Cash at bank and in hand		17,542		29,638	
		45,291		105,949	
Creditors: amounts falling due within one year	4	(1,745)		(119,739)	
Net current assets/(liabilities)			43,546		(13,790)
Total assets less current liabilities			43,546		21,493
Capital and reserves					
Called up share capital	5		4,596		3,061
Share premium account			3,703,373		3,704,909
Profit and loss account	6		(3,664,423)		(3,686,477)
Shareholders' funds			43,546		21,493

The Notes on pages 3 to 5 form an integral part of these accounts

In preparing these financial statements

- For the year ending 30 April 2012 the Company was entitled to exemption from audit under section 477(2) of the Companies Act 2006 relating to the small companies' regime
- The members have not required the Company to obtain an audit in accordance with section 476 of the Companies Act 2006

Company Registration No. 04216368

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)

ABBREVIATED BALANCE SHEET (CONTINUED)

AS AT 30 APRIL 2013

The directors acknowledge their responsibility for

- (i) ensuring the Company keeps accounting records which comply with sections 386 and 387 of the Companies Act 2006, and
 - (ii) preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the Company
- d) These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime

Approved by the Board on 13 December 2013

and signed on its behalf by



Dr Michael J McLean
Director

Company Registration No. 04216368

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 30 APRIL 2013

1 Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

The directors have reviewed the working capital needs of the Company and are fully satisfied that it has sufficient funds to meet all foreseeable future requirements. Therefore the directors have prepared the financial statements on a going concern basis.

1.2 Turnover

Turnover represents amounts receivable for goods and services net of VAT and trade discounts. The Company had no turnover in the year ended 30 April 2013 (2012 £nil).

1.3 Research and development

Research expenditure is written off to the profit and loss account in the year in which it is incurred. Development expenditure is written off in the same way unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit. The Company has not undertaken any new research or development work in the year ended 30 April 2013.

1.4 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Fixtures, fittings & equipment	20% Straight line
--------------------------------	-------------------

The Company has disposed of all of its remaining fixed assets during the year and the accounts show a nil net book value as at 30 April 2013.

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2013

2 Tangible fixed assets (Fixtures, fittings and equipment)

	£
Cost	
At 30 April 2012	96,903
Additions	-
Disposals	(96,903)
	<hr/>
At 30 April 2013	-
	<hr/>
Depreciation	
At 30 April 2012	61,620
Charge for the year	2,905
Disposals	(64,525)
	<hr/>
At 30 April 2013	-
	<hr/>
Net book value	
At 30 April 2013	-
	<hr/>
At 30 April 2012	35,283
	<hr/>

3 Debtors	2013	2012
	£	£
Trade debtors	-	3,700
Other debtors	27,749	72,611
	<hr/>	<hr/>
	27,749	76,311
	<hr/>	<hr/>

4 Creditors: amounts falling due within one year	2013	2012
	£	£
Trade creditors	26	103,343
Other creditors	1,719	16,396
	<hr/>	<hr/>
	1,745	119,739
	<hr/>	<hr/>

2013 Other creditors include £609 owed to a director of the Company 2012 Trade and Other creditors both also included amounts owed to directors of the Company (see Note 7)

PCT SHAREHOLDERS LIMITED (formerly Pro-Cure Therapeutics Limited)

NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2013

5 Share capital	2013	2012
	£	£
Allotted, called up and fully paid		
250,911 A Ordinary shares of 1p each	2,509	1,491
208,699 D Ordinary shares of 1p each	2,087	1,570
	<hr/>	<hr/>
	4,596	3,061
	<hr/>	<hr/>

During the year a special resolution was passed and the 3 C Ordinary shares of 1p each were re-designated as A Ordinary shares of 1p each. In addition there have been bonus issues of 101,811 A Ordinary shares of 1p each and 51,743 D Ordinary shares of 1p each which have been taken as a reduction of £1,536 against share premium.

6 Statement of movements on reserves	Share premium account	Profit and loss account
	£	£
Balance at 1 May 2012	3,704,909	(3,686,477)
Profit for the year		22,054
Share premium – bonus share issue	(1,536)	
	<hr/>	<hr/>
Balance at 30 April 2013	3,703,373	(3,664,423)
	<hr/>	<hr/>

7 Transactions with directors

As at 30 April 2013 Other debtors included £609 owed to Dr J R Knights, a director. As at 30 April 2012, Trade creditors and Other creditors included £13,392 and £6,000, respectively, owed to Dr A J Riddell, Mr P J Duffen and Professor N J Maitland who were then directors of the Company. These amounts were settled in full during the year.

During the year "success fee" and sale commission payments totalling £60,036 were made to two directors (Dr M J McLean and Dr J R Knights) for completing an Asset Purchase Agreement under the terms of which the Company's remaining business and assets were sold to The University of York (see Note 8).

8 Related party transactions

The University of York

During the year the Company entered into an Asset Purchase Agreement with The University of York, a shareholder, whereby the Company's remaining business and assets (primarily its intellectual property rights) were sold to the University for an Initial Consideration of £130,000. As a condition of this Agreement, the Company changed its name on 1 November 2012 from Pro-Cure Therapeutics Limited to PCT Shareholders Limited. In addition, the company sold laboratory and office equipment to the University for £15,718 (2012 £7,150).